ImCheck Therapeutics is designing and developing novel immunotherapeutics that target members of the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules with an initial focus on gamma delta (γ9δ2) T cells. ImCheck’s understanding of these novel targets benefits from the continued involvement of company scientific founder Prof. Daniel Olive (INSERM, CNRS, Institut Paoli Calmettes, Aix-Marseille University), a world-renowned researcher in γ9δ2T cells and BTNs, which has led to identification of additional immune cell populations that can be modulated through BTN(L)s, including tumor associated macrophages (TAMs).
ImCheck’s expertise in antibody-based drug discovery and translational research have enabled us to advance our first immuno-oncology program targeting BTN3A to activate γ9δ2T cells into the clinic in 2020 and to produce a broad pipeline of monoclonal antibody drug candidates.
Due to their mechanism of action, including the ability to simultaneously modulate innate and adaptive immunity, ImCheck's “first-in-class" antibodies may be able to improve upon the first-generation of checkpoint inhibitors in cancer. ImCheck’s programs also have potential in autoimmune and infectious disease indications, which the company is currently investigating.
Leadership Team
Pierre d'EPENOUXChief Executive Officer
Hans Henrik CHRISTENSENChief Financial Officer and
Chief Operating Officer
Claude KNOPFChief Business Officer
Board Members
Thomas CIVIKMBA
Independent Chairman
Michael BARANPhD, MBA
Pfizer Ventures
Rémi DROLLERPhD
Kurma Partners/ Eurazeo
Pierre d'EPENOUXChief Executive Officer
Florent GROSMBA
Earlybird Venture Capital
Karl NÄGLERPhD
Wellington Partners Life Sciences
Thibaut ROULONPhD
Bpifrance
Bram VANPARYSPhD, MBA
Gimv
Raphael WISNIEWSKIAndera Partners
Board Observers
Vincent BRICHARDMD, PhD
EQT Life Sciences
Klaus BREINERPhD
BB Pureos Bioventures
Clinical Advisory Board
Daniel OLIVE, MD, PhDHead of the Immunity and Cancer lab, CRCM.
Professor of Immunology and
Director of the Oncology Research Programs
at Aix Marseille University.
Scientific founder of ImCheck.
Marc BONNEVILLE, DVM, PhDVice President of Medical and
Scientific Affairs at Institut Mérieux.
Richard BULLER, MD, PhDOncology Diagnostic and
Clinical Development
Consulting, LLC.
Johann de BONO, MD, PhDRegius Professor of
Cancer Research.
Professor of Experimental
Cancer Medicine and Honorary
Consultant in Medical Oncology.
Jean Jacques FOURNIE, PhDResearch Director at CNRS
(French National Center for
Scientific Research) in Cancer
Research Center of Toulouse.
Richard D. LOPEZ, MDAssociate Professor of Medicine
Cell Therapy and Hematologic
Malignancies Specialist.
General Oncology.
Patricia LORUSSO, MDProfessor of Medicine
(Medical Oncology),
Associate Center Director
for Innovative Medicine
at Yale Cancer Center.
Aurélien MARABELLE, MD, PhDClinical Director,
Cancer Immunotherapy Program,
Gustave Roussy, Paris.
Director, Translational Research
Laboratory in Immunotherapy,
INSERM.
